Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats
mexiletine, oxaliplatin, neuropathic pain
Gespeichert in:
| Autor*in: |
Nobuaki Egashira [verfasserIn] Shingo Hirakawa [verfasserIn] Takehiro Kawashiri [verfasserIn] Takahisa Yano [verfasserIn] Hiroaki Ikesue [verfasserIn] Ryozo Oishi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2010 |
|---|
| Übergeordnetes Werk: |
In: Journal of Pharmacological Sciences - Elsevier, 2017, 112(2010), 4, Seite 473-476 |
|---|---|
| Übergeordnetes Werk: |
volume:112 ; year:2010 ; number:4 ; pages:473-476 |
| Links: |
|---|
| DOI / URN: |
10.1254/jphs.10012SC |
|---|
| Katalog-ID: |
DOAJ053247094 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ053247094 | ||
| 003 | DE-627 | ||
| 005 | 20230502235656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1254/jphs.10012SC |2 doi | |
| 035 | |a (DE-627)DOAJ053247094 | ||
| 035 | |a (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Nobuaki Egashira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain | ||
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Shingo Hirakawa |e verfasserin |4 aut | |
| 700 | 0 | |a Takehiro Kawashiri |e verfasserin |4 aut | |
| 700 | 0 | |a Takahisa Yano |e verfasserin |4 aut | |
| 700 | 0 | |a Hiroaki Ikesue |e verfasserin |4 aut | |
| 700 | 0 | |a Ryozo Oishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pharmacological Sciences |d Elsevier, 2017 |g 112(2010), 4, Seite 473-476 |w (DE-627)1760631620 |x 13478613 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2010 |g number:4 |g pages:473-476 |
| 856 | 4 | 0 | |u https://doi.org/10.1254/jphs.10012SC |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1347861319309855 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1347-8613 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2010 |e 4 |h 473-476 | ||
| author_variant |
n e ne s h sh t k tk t y ty h i hi r o ro |
|---|---|
| matchkey_str |
article:13478613:2010----::eieieeessxlpaiidcderp |
| hierarchy_sort_str |
2010 |
| callnumber-subject-code |
RM |
| publishDate |
2010 |
| allfields |
10.1254/jphs.10012SC doi (DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain Therapeutics. Pharmacology Shingo Hirakawa verfasserin aut Takehiro Kawashiri verfasserin aut Takahisa Yano verfasserin aut Hiroaki Ikesue verfasserin aut Ryozo Oishi verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 112(2010), 4, Seite 473-476 (DE-627)1760631620 13478613 nnns volume:112 year:2010 number:4 pages:473-476 https://doi.org/10.1254/jphs.10012SC kostenfrei https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861319309855 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 112 2010 4 473-476 |
| spelling |
10.1254/jphs.10012SC doi (DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain Therapeutics. Pharmacology Shingo Hirakawa verfasserin aut Takehiro Kawashiri verfasserin aut Takahisa Yano verfasserin aut Hiroaki Ikesue verfasserin aut Ryozo Oishi verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 112(2010), 4, Seite 473-476 (DE-627)1760631620 13478613 nnns volume:112 year:2010 number:4 pages:473-476 https://doi.org/10.1254/jphs.10012SC kostenfrei https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861319309855 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 112 2010 4 473-476 |
| allfields_unstemmed |
10.1254/jphs.10012SC doi (DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain Therapeutics. Pharmacology Shingo Hirakawa verfasserin aut Takehiro Kawashiri verfasserin aut Takahisa Yano verfasserin aut Hiroaki Ikesue verfasserin aut Ryozo Oishi verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 112(2010), 4, Seite 473-476 (DE-627)1760631620 13478613 nnns volume:112 year:2010 number:4 pages:473-476 https://doi.org/10.1254/jphs.10012SC kostenfrei https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861319309855 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 112 2010 4 473-476 |
| allfieldsGer |
10.1254/jphs.10012SC doi (DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain Therapeutics. Pharmacology Shingo Hirakawa verfasserin aut Takehiro Kawashiri verfasserin aut Takahisa Yano verfasserin aut Hiroaki Ikesue verfasserin aut Ryozo Oishi verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 112(2010), 4, Seite 473-476 (DE-627)1760631620 13478613 nnns volume:112 year:2010 number:4 pages:473-476 https://doi.org/10.1254/jphs.10012SC kostenfrei https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861319309855 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 112 2010 4 473-476 |
| allfieldsSound |
10.1254/jphs.10012SC doi (DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain Therapeutics. Pharmacology Shingo Hirakawa verfasserin aut Takehiro Kawashiri verfasserin aut Takahisa Yano verfasserin aut Hiroaki Ikesue verfasserin aut Ryozo Oishi verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 112(2010), 4, Seite 473-476 (DE-627)1760631620 13478613 nnns volume:112 year:2010 number:4 pages:473-476 https://doi.org/10.1254/jphs.10012SC kostenfrei https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861319309855 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 112 2010 4 473-476 |
| language |
English |
| source |
In Journal of Pharmacological Sciences 112(2010), 4, Seite 473-476 volume:112 year:2010 number:4 pages:473-476 |
| sourceStr |
In Journal of Pharmacological Sciences 112(2010), 4, Seite 473-476 volume:112 year:2010 number:4 pages:473-476 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Journal of Pharmacological Sciences |
| authorswithroles_txt_mv |
Nobuaki Egashira @@aut@@ Shingo Hirakawa @@aut@@ Takehiro Kawashiri @@aut@@ Takahisa Yano @@aut@@ Hiroaki Ikesue @@aut@@ Ryozo Oishi @@aut@@ |
| publishDateDaySort_date |
2010-01-01T00:00:00Z |
| hierarchy_top_id |
1760631620 |
| id |
DOAJ053247094 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053247094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502235656.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1254/jphs.10012SC</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053247094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shingo Hirakawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takahisa Yano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroaki Ikesue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryozo Oishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">112(2010), 4, Seite 473-476</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:112</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:473-476</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1254/jphs.10012SC</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861319309855</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">112</subfield><subfield code="j">2010</subfield><subfield code="e">4</subfield><subfield code="h">473-476</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Nobuaki Egashira |
| spellingShingle |
Nobuaki Egashira misc RM1-950 misc Therapeutics. Pharmacology Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| authorStr |
Nobuaki Egashira |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760631620 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| issn |
13478613 |
| topic_title |
RM1-950 Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| topic |
misc RM1-950 misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Pharmacological Sciences |
| hierarchy_parent_id |
1760631620 |
| hierarchy_top_title |
Journal of Pharmacological Sciences |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760631620 |
| title |
Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| ctrlnum |
(DE-627)DOAJ053247094 (DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb |
| title_full |
Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| author_sort |
Nobuaki Egashira |
| journal |
Journal of Pharmacological Sciences |
| journalStr |
Journal of Pharmacological Sciences |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2010 |
| contenttype_str_mv |
txt |
| container_start_page |
473 |
| author_browse |
Nobuaki Egashira Shingo Hirakawa Takehiro Kawashiri Takahisa Yano Hiroaki Ikesue Ryozo Oishi |
| container_volume |
112 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nobuaki Egashira |
| doi_str_mv |
10.1254/jphs.10012SC |
| author2-role |
verfasserin |
| title_sort |
mexiletine reverses oxaliplatin-induced neuropathic pain in rats |
| callnumber |
RM1-950 |
| title_auth |
Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| abstract |
Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain |
| abstractGer |
Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain |
| abstract_unstemmed |
Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats |
| url |
https://doi.org/10.1254/jphs.10012SC https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb http://www.sciencedirect.com/science/article/pii/S1347861319309855 https://doaj.org/toc/1347-8613 |
| remote_bool |
true |
| author2 |
Shingo Hirakawa Takehiro Kawashiri Takahisa Yano Hiroaki Ikesue Ryozo Oishi |
| author2Str |
Shingo Hirakawa Takehiro Kawashiri Takahisa Yano Hiroaki Ikesue Ryozo Oishi |
| ppnlink |
1760631620 |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1254/jphs.10012SC |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T16:38:08.587Z |
| _version_ |
1803576607859802112 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053247094</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502235656.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1254/jphs.10012SC</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053247094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ39865dd2ca494ed8b14cfc96c6f5aebb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na+-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically. Keywords:: mexiletine, oxaliplatin, neuropathic pain</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shingo Hirakawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takahisa Yano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroaki Ikesue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryozo Oishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">112(2010), 4, Seite 473-476</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:112</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:473-476</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1254/jphs.10012SC</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/39865dd2ca494ed8b14cfc96c6f5aebb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861319309855</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">112</subfield><subfield code="j">2010</subfield><subfield code="e">4</subfield><subfield code="h">473-476</subfield></datafield></record></collection>
|
| score |
7.3982906 |